Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05443802
Other study ID # APHP210081
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 16, 2022
Est. completion date February 16, 2025

Study information

Verified date November 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Damien Roux, PhD
Phone 1 47 60 63 29
Email damien.roux@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetic ketoacidosis (DKA), a frequent complication of diabetes, is the consequence of a profound insulin deficiency responsible for osmotic polyuria and thus major losses of water, glucose, sodium and potassium as well as a metabolic acidosis due to the uncontrolled production of ketonic acids. Management includes fluid replacement, insulin therapy and correction of metabolic disorders (including potassium loss). Initially described in patients with type 1 diabetes (T1D), it is now often observed in patients with type 2 diabetes (T2D) in whom it is more a matter of insulin resistance than an absolute deficiency. However, international guidelines recommend a similar dose of intravenous insulin (0.10 IU/kg/hour) regardless of the type of diabetes. During treatment, metabolic complications are frequent and potentially serious, especially in T2D due to cardiovascular comorbidities. The research hypothesis is that decreasing the insulin dose will reduce metabolic complications without influencing time to resolution in adult patients, regardless of diabetes type.


Description:

Diabetic ketoacidosis (DKA), a frequent complication of diabetes, is the consequence of a profound insulin deficiency responsible for osmotic polyuria which leads to major losses of water, sodium and potassium as well as the generation of metabolic acidosis due to the uncontrolled production of ketonic acids. Management includes fluid replacement, insulin therapy and correction of metabolic disorders (including potassium loss and acidosis). Initially described in patients with type 1 diabetes (T1D), it is now often observed in patients with type 2 diabetes (T2D) in whom it is more insulin resistance than absolute deficiency. However, international guidelines recommend a similar dosage of intravenous insulin (0.10 IU/kg/hour) regardless of the type of diabetes. During treatment, metabolic complications are frequent and potentially serious, especially in T2D due to cardiovascular comorbidities. A British study reported 27.6% hypoglycaemia and 55% hypokalemia during the first 24 hours of treatment. Comparable figures were observed by conducting a multicenter retrospective study of 122 patients: hypokalaemia and hypoglycaemia were observed in nearly two thirds of cases. A pediatric study showed that a lower dose of insulin (0.05 IU/kg/h) reduced the rate of hypoglycaemia (20% vs 4%) and hypokalaemia (48% vs 20%) compared to at the standard dose (0.10 IU/kg/h) without modifying the time to resolution. But the very small number (25 children per arm), the questionable statistical analysis and the pediatric population (T1D only) do not make it possible to anticipate the potential benefit in a much more heterogeneous adult population. The hypothesis of the research is that decreasing the insulin dose will reduce metabolic complications without influencing time to resolution in adult patients, regardless of diabetes type.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date February 16, 2025
Est. primary completion date August 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient aged 18 years or above - Admission in Intense/Intermediate Care Unit - Severe DKA due to all types of diabetes (T1D, T2D and secondary diabetes and inaugural ketoacidosis) defined by association of the following 3 parameters: - glucose > 11 mmol/L or affirmation of having diabetes - ketonemia > 3mmol/L or ketonuria = 2 - bicarbonate < 15 mmol/L and/or venous pH < or=7.3 - Randomization possible before 15UI of insulin administrated in total - Informed and written consent. In the absence of parent/ relative/ person of trust, the patient may be included via the emergency procedure and consent will be obtained as soon as possible Exclusion Criteria: - Non-diabetic ketoacidosis (fasting or alcoholic) - Patient weighing less than 30 kg - Hypokalemia < 3.5 mmol/L at the time of inclusion - Hyperosmolar hyperglycemic state (defined as efficient plasma osmolarity > 320 mosmol/L) - Absence of social security coverage - Pregnant or breastfeeding patient - Patient under tutelage or curators - Patient deprived of liberty due to a judicial or administrative decision - Patient with a renal disease requiring dialysis - Acute or chronic liver failure with Factor V < 50% - Patient receiving a high dose of corticosteroids (= 0.5 mg/kg) daily - Patient included in another interventional study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Insulin 0.05 IU/kg/h
In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
Insulin 0.10 IU/kg/h
In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.

Locations

Country Name City State
France Louis Mourier Hospital Colombes

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Metabolic complications Proportion of patients with metabolic complications (hypokalaemia <3.5 mmol/L and/or hypoglycemia <3.9 mmol/L) treated with a reduced dose of insulin (0.05 IU/kg/h) compared with the control group receiving the 0.10 IU/kg/h dose. 48 hours
Secondary Resolution of diabetic ketoacidosis Time in hours between randomisation and resolution of diabetic ketoacidosis (defined by ph>7.3 and ketonemia < 3 mmol/L and bicarbonates> 15 mmol/L) 48 hours
Secondary Episode of hypokalaemia Proportion of patients with at least one episode of hypokalaemia < 3.5 mmol/L between randomization and resolution of DKA 48 hours
Secondary Episode of hypoglycemia Proportion of patients with at least one episode of hypoglycemia < 3.9 mmol/L between randomization and resolution of DKA 48 hours
Secondary Episode of severe hypoglycemia Proportion of patients with at least one episode of hypoglycemia < 2.9 mmol/L between randomization and resolution of DKA 48 hours
Secondary Cardiac arrythmia diagnosed by EKG Proportion of patients with onset of new cardiac arrhythmia diagnosed by EKG analysis (atrial fibrillation and ventricular arrhythmia) and scopic monitoring between randomization and resolution of DKA 48 hours
Secondary Glucose infusion 1000mL Proportion of patients who received more than 1000 mL of 10% glucose solution (indicating tendency of hypoglycemia) between randomization and resolution of DKA or 48h after inclusion if DKA is unresolved 48 hours
Secondary Glucose infusion of 30% glucose solution Proportion of patients who received one perfusion of 30% glucose solution between randomization and resolution of DKA or 48h after inclusion if DKA is unresolved 48 hours
Secondary Amount of glucose perfused Amount of glucose perfused (in grams) (glucose 5%, 10% and 30%) between randomization and resolution of the DKA or 48 hours after inclusion if the DKA is not resolved 48 hours
Secondary Potassium intake Potassium intake (in grams) orally and intravenously between patient randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved 48 hours
Secondary Length of stay in ICU Duration of stay (in hours) in ICU 48 hours
Secondary Time between patient randomization and resolution of DKA in T1D population Time in hours between patient randomization and resolution of DKA in T1D population 48 hours
Secondary Time between patient randomization and resolution of DKA in T2D population Time in hours between patient randomization and resolution of DKA in T2D population 48 hours
Secondary Time between patient randomization and resolution of DKA in patients suffering from first ketoacidosis episode Time in hours between patient randomization and resolution of DKA in patients suffering from ketoacidosis 48 hours
Secondary Episode of hypokalaemia in T1D population Proportion of patients with at least one episode of hypokalaemia < 3.5 mmol/L between randomisation and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T1D population 48 hours
Secondary Episode of hypokalaemia in T2D population Proportion of patients with at least one episode of hypokalaemia < 3.5 mmol/L between randomisation and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T2D population 48 hours
Secondary Episode of hypokalaemia in patients suffering from first ketoacidosis episode Proportion of patients with at least one episode of hypokalaemia < 3.5 mmol/L between randomisation and resolution of DKA or 48 hours after inclusion if DKA is not resolved within inaugural ketoacidosis population 48 hours
Secondary Episode of hypoglycaemia in T1D population Proportion of patients with at least one episode of hypoglycaemia < 3.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T1D population 48 hours
Secondary Episode of hypoglycaemia in T2D population Proportion of patients with at least one episode of hypoglycaemia < 3.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T2D population 48 hours
Secondary Episode of hypoglycaemia in patients suffering from first ketoacidosis episode Proportion of patients with at least one episode of hypoglycaemia < 3.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within inaugural ketoacidosis population 48 hours
Secondary Episode of severe hypoglycaemia in T1D population Proportion of patients with at least one episode of severe hypoglycaemia < 2.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T1D population 48 hours
Secondary Episode of severe hypoglycaemia in T2D population Proportion of patients with at least one episode of severe hypoglycaemia < 2.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within T2D population 48 hours
Secondary Episode of severe hypoglycaemia in patients suffering from first ketoacidosis episode Proportion of patients with at least one episode of severe hypoglycaemia < 2.9 mmol/L between randomization and resolution of DKA or 48 hours after inclusion if DKA is not resolved within inaugural ketoacidosis population 48 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT03660189 - Two Bag System for Diabetic Ketoacidosis N/A
Terminated NCT03066440 - Double Blinded Randomized Control Trial of Types of IVF in Children With DKA Phase 4
Completed NCT04940897 - Use of Blood Ketone Meters to Improve Ambulance Hyperglycaemia Care N/A
Completed NCT02930044 - Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis N/A
Completed NCT04926740 - Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department N/A
Terminated NCT04567225 - Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management Phase 4
Completed NCT04017221 - Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes
Recruiting NCT03717896 - Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis Phase 2
Terminated NCT02548494 - Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes N/A
Completed NCT02006342 - Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis N/A
Completed NCT01753921 - Evaluation of a Non-invasive Brain Compliance Measurement Device
Completed NCT01365793 - Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis Phase 3
Completed NCT00426413 - Ketosis Prone Diabetes in African-Americans N/A
Not yet recruiting NCT05867797 - Risk Factors and Outcomes of Acute Kidney Injury in Patients With Diabetic Ketoacidosis at Sohag University Hospital.
Terminated NCT04234867 - Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) Phase 1
Not yet recruiting NCT05752279 - Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis Phase 3
Completed NCT04825639 - Identifying Risk Factors for Developing AKI in Sepsis
Recruiting NCT05155917 - Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care Phase 2
Recruiting NCT05383404 - Clinical and Laboratory Parameters Associated With Different Degrees of Dehydration Among Children With Diabetic Ketoacidosis